$OVTZ
OCULUS VISIONTECH INC.

2024 Q2 Form 10-Q Financial Statement

#000143774924016483 Filed on May 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $46.06K $47.18K
YoY Change -5.76% -35.17%
% of Gross Profit
Research & Development $2.551K $2.180K
YoY Change -46.11% -97.41%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $48.61K $49.36K
YoY Change -9.32% -68.55%
Operating Profit
YoY Change
Interest Expense $672.00 $1.440K
YoY Change -78.94% -53.47%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$79.97K -$82.82K
YoY Change -33.5% -64.77%
Income Tax
% Of Pretax Income
Net Earnings -$79.97K -$82.82K
YoY Change -33.5% -64.77%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 91.42M 91.42M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $29.71K $94.71K
YoY Change -91.1% -82.12%
Cash & Equivalents $29.71K $94.71K
Short-Term Investments
Other Short-Term Assets $7.420K $11.72K
YoY Change -2.24% -2.98%
Inventory
Prepaid Expenses $7.421K $11.72K
Receivables
Other Receivables
Total Short-Term Assets $44.89K $110.2K
YoY Change -86.9% -79.72%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets -$2.00 $3.00
YoY Change -33.33%
TOTAL ASSETS
Total Short-Term Assets $44.89K $110.2K
Total Long-Term Assets -$2.00 $3.00
Total Assets $44.89K $110.2K
YoY Change -86.9% -79.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $80.76K $83.27K
YoY Change -55.91% -68.59%
Accrued Expenses $15.26K $30.53K
YoY Change 28.02% -17.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $292.2K $279.0K
YoY Change 31.92% -14.96%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $292.2K $279.0K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $292.2K $279.0K
YoY Change 31.92% -14.96%
SHAREHOLDERS EQUITY
Retained Earnings -$48.55M -$48.47M
YoY Change 0.83% 0.91%
Common Stock $46.85M $46.85M
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$247.3K -$168.8K
YoY Change
Total Liabilities & Shareholders Equity $44.89K $110.2K
YoY Change -86.9% -79.72%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$79.97K -$82.82K
YoY Change -33.5% -64.77%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$65.15K -$61.29K
YoY Change -66.94% -60.9%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities -65.15K -$61.29K
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash -65.15K -$61.86K
YoY Change -66.94% -60.82%
FREE CASH FLOW
Cash From Operating Activities -$65.15K -$61.29K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
V6C 3N6
CY2024Q1 dei City Area Code
CityAreaCode
604
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
685-1017
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2023Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
250000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
250000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91422569
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91422569
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
91422569
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91422569
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91422569
CY2024Q1 ovtz Common Stock Shares Held In Escrow
CommonStockSharesHeldInEscrow
0
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
0-29651
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
WY
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
06-1576391
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Suite 507 - 837 West Hastings Street
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Vancouver
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
BC
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
91422569
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94711 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
156574 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15502 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
27381 usd
CY2024Q1 us-gaap Assets
Assets
110213 usd
CY2023Q4 us-gaap Assets
Assets
183955 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
278975 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
273723 usd
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
46850710 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
46850710 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1483423 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1479031 usd
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-33433 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-32863 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48469462 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48386646 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-168762 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-89768 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
110213 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
183955 usd
CY2024Q1 ovtz Consulting Expense
ConsultingExpense
30500 usd
CY2023Q1 ovtz Consulting Expense
ConsultingExpense
45000 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2180 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84203 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47184 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
72777 usd
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4392 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
36174 usd
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
84256 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
238154 usd
CY2024Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1440 usd
CY2023Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
3095 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-82816 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-235059 usd
CY2024Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-570 usd
CY2023Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-1159 usd
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-83386 usd
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-236218 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91422569
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
91422569
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-82816 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-235059 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4392 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
36174 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-11879 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-16510 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-22445 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
25624 usd
CY2024Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
27697 usd
CY2023Q1 us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
0 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-61293 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-156751 usd
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-570 usd
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1159 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-61863 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-157910 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
156574 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
687602 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
94711 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
529692 usd
CY2024Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
0 usd
CY2024Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-82816 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-235059 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48469462 usd
CY2024Q1 ovtz Working Capital Deficit
WorkingCapitalDeficit
168762 usd
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11717 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
16014 usd
CY2024Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
3785 usd
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
11367 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
15502 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
27381 usd
CY2024Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
91422569
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
250000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4392 usd
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
36174 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5415000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.5
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
3850000
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.36
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1565000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.85
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
500000
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
1.2
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1065000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.69
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1065000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
927000
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
17400000
CY2023Q4 ovtz Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.28
CY2024Q1 ovtz Class Of Warrant Or Right Expired During Period
ClassOfWarrantOrRightExpiredDuringPeriod
4900000
CY2024Q1 ovtz Class Of Warrant Or Right Expired During Period Weighted Average Exercise Price
ClassOfWarrantOrRightExpiredDuringPeriodWeightedAverageExercisePrice
1
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12500000
CY2024Q1 ovtz Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.001
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
12500000
CY2024Q1 ovtz Filing And Regulatory Fee
FilingAndRegulatoryFee
11447 usd
CY2023Q1 ovtz Filing And Regulatory Fee
FilingAndRegulatoryFee
12577 usd
CY2024Q1 us-gaap Professional Fees
ProfessionalFees
11685 usd
CY2023Q1 us-gaap Professional Fees
ProfessionalFees
14091 usd
CY2024Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
10885 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
10813 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13167 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
35296 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47184 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
72777 usd
CY2024Q1 us-gaap Research And Development Expense Software Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost
2180 usd
CY2023Q1 us-gaap Research And Development Expense Software Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost
49765 usd
CY2024Q1 ovtz Research And Development Expense Business Development
ResearchAndDevelopmentExpenseBusinessDevelopment
0 usd
CY2023Q1 ovtz Research And Development Expense Business Development
ResearchAndDevelopmentExpenseBusinessDevelopment
3952 usd
CY2024Q1 ovtz Research And Development Expense Payroll
ResearchAndDevelopmentExpensePayroll
0 usd
CY2023Q1 ovtz Research And Development Expense Payroll
ResearchAndDevelopmentExpensePayroll
30486 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2180 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84203 usd
CY2024Q1 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
44196 usd
CY2023Q1 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
61811 usd
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
94711 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
156574 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
278975 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
273723 usd

Files In Submission

Name View Source Status
0001437749-24-016483-index-headers.html Edgar Link pending
0001437749-24-016483-index.html Edgar Link pending
0001437749-24-016483.txt Edgar Link pending
0001437749-24-016483-xbrl.zip Edgar Link pending
ex_670649.htm Edgar Link pending
ex_670650.htm Edgar Link pending
ex_670651.htm Edgar Link pending
ex_670652.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
logo01.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
ovtz-20240331.xsd Edgar Link pending
ovtz20240331_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
ovtz20240331_10q_htm.xml Edgar Link completed
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ovtz-20240331_cal.xml Edgar Link unprocessable
ovtz-20240331_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
ovtz-20240331_lab.xml Edgar Link unprocessable
ovtz-20240331_pre.xml Edgar Link unprocessable